Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by PTBaileyon Sep 27, 2021 1:09pm
119 Views
Post# 33924511

RE:Update?

RE:Update?
bud13 wrote:
will we ever get a update on what's going on? This starting date seems like it's not going to happen . The delay before was waiting for a refund from the Aussie's. Now we got it will it disappear before anything happens then we will have another reason for a no start date. I'm hoping not as it will just bring us back to old days. Any thoughts HIgh?


Supposedly TSX want clarification on deal between Claritas and Obsidian. This was an email I got from Bob on Sept. 20 and I belive they are expecting things to be cleared up this week.

We are still awaiting TSXV approval of the USD $1M convertible debenture financing.
 
It is a frustrating process for the following reasons:
  • The analyst assigned to our submission stated that the transaction terms were different from transactions he had approved previously, and therefore he needed to refer our submission to the Executive Listing committee.
  • The Committee was unable to take any action for the past 2 weeks due to the fact that at least one member was away on vacation.
  • The person who was on vacation has returned today, but the Committee is not scheduled to meet until Thursday this week.
In the meantime, we have answered a series of questions from the analyst, and have tried to escalate the matter to senior management at the TSXV.
 
Bob

<< Previous
Bullboard Posts
Next >>